Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.59 |
| ▸ | MAPK13 | O15264 | 6/20 | 0.59 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.59 |
| ▸ | MAPK11 | Q15759 | 6/20 | 0.59 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | TEK | Q02763 | 1/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11016914 | 0.81 | KMT2A (0.43) | MAPK14MAPK13MAPK12MAPK11RAB9A | |
| SCHEMBL10966368 | 0.81 | LMNA (0.50) | MAPK14MAPK13MAPK12MAPK11RAB9A | |
| SCHEMBL10964771 | 0.80 | MEN1 (0.48) | MAPK14MAPK13MAPK12MAPK11RAB9A | |
| SCHEMBL10809999 | 0.79 | VCP (0.44) | MAPK14MAPK13MAPK12MAPK11RAB9A | |
| SCHEMBL10989518 | 0.78 | ALDH1A1 (0.47) | RAB9ALMNANPC1MAPTKDM4E | |
| SCHEMBL5443200 | 0.78 | ALDH1A1 (0.47) | LMNAMAPTKDM4EALDH1A1NPSR1 | |
| SCHEMBL13937116 | 0.76 | LMNA (0.60) | RAB9ASMN1; SMN2LMNANPC1MAPT | |
| SCHEMBL5451982 | 0.75 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11KDM4E | |
| SCHEMBL10915111 | 0.74 | ALDH1A1 (0.66) | RAB9ASMN1; SMN2LMNANPC1MAPT | |
| SCHEMBL9539522 | 0.73 | NPSR1 (0.50) | RAB9ASMN1; SMN2LMNANPC1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| EP-0772601-B1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-1211244-A2 | 4,5-substitued imidazolyl compounds for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-06-05 | — | — | EP | disclosed |
| US-5620999-A | ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT | G.D. SEARLE & CO. | 1997-04-15 | — | — | US | disclosed |
| EP-0046451-A2 | Diaryl-imidazole compounds, methods for their preparation, pharmaceutical drugs containing them and their use | CIBA-GEIGY AG (CH) | 1982-02-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | MAPK14 1523/4885MAPK13 2251/4885MAPK12 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.